Literature DB >> 23929624

Structure-guided rational design of α/β-peptide foldamers with high affinity for BCL-2 family prosurvival proteins.

Brian J Smith1, Erinna F Lee, James W Checco, Marco Evangelista, Samuel H Gellman, W Douglas Fairlie.   

Abstract

We have used computational methods to improve the affinity of a foldamer ligand for its target protein. The effort began with a previously reported α/β-peptide based on the BH3 domain of the proapoptotic protein Puma; this foldamer binds tightly to Bcl-x(L) but weakly to Mcl-1. The crystal structure of the Puma-derived α/β-peptide complexed to Bcl-x(L) was used as the basis for computational design of variants intended to display improved binding to Mcl-1. Molecular modelling suggested modification of three α residues of the original α/β backbone. Individually, each substitution caused only a modest (4- to 15-fold) gain in affinity; however, together the three substitutions led to a 250-fold increase in binding to Mcl-1. These modifications had very little effect on affinity for Bcl-x(L). Crystal structures of a number of the new α/β-peptides bound to either Mcl-1 or Bcl-x(L) validated the selection of each substitution. Overall, our findings demonstrate that structure-guided rational design can be used to improve affinity and alter partner selectivity of peptidic ligands with unnatural backbones that bind to specific protein partners.
Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  BH3 domain; Mcl-1; apoptosis; peptide design; peptidomimetics

Mesh:

Substances:

Year:  2013        PMID: 23929624      PMCID: PMC3970217          DOI: 10.1002/cbic.201300351

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  57 in total

1.  Extending foldamer design beyond α-helix mimicry: α/β-peptide inhibitors of vascular endothelial growth factor signaling.

Authors:  Holly S Haase; Kimberly J Peterson-Kaufman; Sheeny K Lan Levengood; James W Checco; William L Murphy; Samuel H Gellman
Journal:  J Am Chem Soc       Date:  2012-05-01       Impact factor: 15.419

2.  Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance.

Authors:  Brett D Welch; J Nicholas Francis; Joseph S Redman; Suparna Paul; Matthew T Weinstock; Jacqueline D Reeves; Yolanda S Lie; Frank G Whitby; Debra M Eckert; Christopher P Hill; Michael J Root; Michael S Kay
Journal:  J Virol       Date:  2010-08-18       Impact factor: 5.103

3.  Mutation to Bax beyond the BH3 domain disrupts interactions with pro-survival proteins and promotes apoptosis.

Authors:  Peter E Czabotar; Erinna F Lee; Geoff V Thompson; Ahmad Z Wardak; W Douglas Fairlie; Peter M Colman
Journal:  J Biol Chem       Date:  2011-01-03       Impact factor: 5.157

4.  Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia.

Authors:  Stefan P Glaser; Erinna F Lee; Evelyn Trounson; Philippe Bouillet; Andrew Wei; W Douglas Fairlie; David J Izon; Johannes Zuber; Amy R Rappaport; Marco J Herold; Warren S Alexander; Scott W Lowe; Lorraine Robb; Andreas Strasser
Journal:  Genes Dev       Date:  2012-01-15       Impact factor: 11.361

5.  Stabilizing the pro-apoptotic BimBH3 helix (BimSAHB) does not necessarily enhance affinity or biological activity.

Authors:  Toru Okamoto; Kerry Zobel; Anna Fedorova; Clifford Quan; Hong Yang; Wayne J Fairbrother; David C S Huang; Brian J Smith; Kurt Deshayes; Peter E Czabotar
Journal:  ACS Chem Biol       Date:  2012-12-10       Impact factor: 5.100

6.  Structural basis of Bcl-xL recognition by a BH3-mimetic α/β-peptide generated by sequence-based design.

Authors:  Erinna F Lee; Brian J Smith; W Seth Horne; Kelsey N Mayer; Marco Evangelista; Peter M Colman; Samuel H Gellman; W Douglas Fairlie
Journal:  Chembiochem       Date:  2011-07-08       Impact factor: 3.164

7.  Evaluation of diverse α/β-backbone patterns for functional α-helix mimicry: analogues of the Bim BH3 domain.

Authors:  Melissa D Boersma; Holly S Haase; Kimberly J Peterson-Kaufman; Erinna F Lee; Oliver B Clarke; Peter M Colman; Brian J Smith; W Seth Horne; W Douglas Fairlie; Samuel H Gellman
Journal:  J Am Chem Soc       Date:  2011-12-08       Impact factor: 15.419

8.  Multiple N-methylation of MT-II backbone amide bonds leads to melanocortin receptor subtype hMC1R selectivity: pharmacological and conformational studies.

Authors:  Lucas Doedens; Florian Opperer; Minying Cai; Johannes G Beck; Matt Dedek; Erin Palmer; Victor J Hruby; Horst Kessler
Journal:  J Am Chem Soc       Date:  2010-06-16       Impact factor: 15.419

9.  The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer.

Authors:  Michelle L Stewart; Emiko Fire; Amy E Keating; Loren D Walensky
Journal:  Nat Chem Biol       Date:  2010-06-20       Impact factor: 15.040

10.  Selective induction of cell death in melanoma cell lines through targeting of Mcl-1 and A1.

Authors:  Daniela Senft; Carola Berking; Saskia A Graf; Claudia Kammerbauer; Thomas Ruzicka; Robert Besch
Journal:  PLoS One       Date:  2012-01-24       Impact factor: 3.240

View more
  30 in total

Review 1.  Targeting recognition surfaces on natural proteins with peptidic foldamers.

Authors:  James W Checco; Samuel H Gellman
Journal:  Curr Opin Struct Biol       Date:  2016-07-05       Impact factor: 6.809

2.  α/β-Peptide Foldamers Targeting Intracellular Protein-Protein Interactions with Activity in Living Cells.

Authors:  James W Checco; Erinna F Lee; Marco Evangelista; Nerida J Sleebs; Kelly Rogers; Anne Pettikiriarachchi; Nadia J Kershaw; Geoffrey A Eddinger; David G Belair; Julia L Wilson; Chelcie H Eller; Ronald T Raines; William L Murphy; Brian J Smith; Samuel H Gellman; W Douglas Fairlie
Journal:  J Am Chem Soc       Date:  2015-08-28       Impact factor: 15.419

3.  Structural insights into BCL2 pro-survival protein interactions with the key autophagy regulator BECN1 following phosphorylation by STK4/MST1.

Authors:  Erinna F Lee; Nicholas A Smith; Tatiana P Soares da Costa; Nastaran Meftahi; Shenggen Yao; Tiffany J Harris; Sharon Tran; Anne Pettikiriarachchi; Matthew A Perugini; David W Keizer; Marco Evangelista; Brian J Smith; W Douglas Fairlie
Journal:  Autophagy       Date:  2019-01-09       Impact factor: 16.016

4.  Exploring Protein-Protein Interactions as Drug Targets for Anti-cancer Therapy with In Silico Workflows.

Authors:  Alexander Goncearenco; Minghui Li; Franco L Simonetti; Benjamin A Shoemaker; Anna R Panchenko
Journal:  Methods Mol Biol       Date:  2017

5.  Cell death and the mitochondria: therapeutic targeting of the BCL-2 family-driven pathway.

Authors:  M J Roy; A Vom; P E Czabotar; G Lessene
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

6.  Iterative Nonproteinogenic Residue Incorporation Yields α/β-Peptides with a Helix-Loop-Helix Tertiary Structure and High Affinity for VEGF.

Authors:  James W Checco; Samuel H Gellman
Journal:  Chembiochem       Date:  2017-01-09       Impact factor: 3.164

7.  Residue-Based Preorganization of BH3-Derived α/β-Peptides: Modulating Affinity, Selectivity and Proteolytic Susceptibility in α-Helix Mimics.

Authors:  Kimberly J Peterson-Kaufman; Holly S Haase; Melissa D Boersma; Erinna F Lee; W Douglas Fairlie; Samuel H Gellman
Journal:  ACS Chem Biol       Date:  2015-05-07       Impact factor: 5.100

8.  Rotamer Libraries for the High-Resolution Design of β-Amino Acid Foldamers.

Authors:  Andrew M Watkins; Timothy W Craven; P Douglas Renfrew; Paramjit S Arora; Richard Bonneau
Journal:  Structure       Date:  2017-10-12       Impact factor: 5.006

Review 9.  Folding and function in α/β-peptides: targets and therapeutic applications.

Authors:  Halina M Werner; W Seth Horne
Journal:  Curr Opin Chem Biol       Date:  2015-06-30       Impact factor: 8.822

Review 10.  Small molecule Mcl-1 inhibitors for the treatment of cancer.

Authors:  Johannes Belmar; Stephen W Fesik
Journal:  Pharmacol Ther       Date:  2014-08-27       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.